Moratorium on Gain-of-Function Research

In the wake of a handful of biosafety lapses at federal research facilities, the US government is temporarily halting funding for new studies aiming to give novel functions to influenza, SARS, and MERS viruses.

Written byJef Akst
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

WIKIMEDIA, R. BEKTAEVThe White House Office of Science and Technology Policy (OSTP) and Department of Health and Human Services last week (October 17) announced it was launching a detailed review into so-called gain-of-function research, in which pathogens are manipulated to alter their capabilities. Such research made headlines in 2012 after two groups instilled the avian influenza virus H5N1 with the ability to transmit between ferrets through the air—a feat that prompted a year-long moratorium on H5N1 research. Now, in the face of threats like influenza, SARS, and MERS, which have killed scores in the Middle East and Asia, the government is instituting a pause to gain-of-function funding for experiments involving these deadly viruses.

“NIH has funded such studies because they help define the fundamental nature of human-pathogen interactions, enable the assessment of the pandemic potential of emerging infectious agents, and inform public health and preparedness efforts,” National Institutes of Health Director Francis Collins said in a statement. “These studies, however, also entail biosafety and biosecurity risks, which need to be understood better.”

The move comes after as many as 75 scientists at the US Centers for Disease Control and Prevention (CDC) were exposed to anthrax in June and, a few weeks later, US Food and Drug Administration (FDA) employees found 16 forgotten vials of smallpox in storage. Last month, the government released new regulations regarding dual-use research, but interestingly, gain-of-function research was omitted from the report. Now, the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies